Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) [B-cell lymphoma] with pentostatin, alemtuzumab, and low dose rituximab: A phase II clinical trial.

Trial Profile

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) [B-cell lymphoma] with pentostatin, alemtuzumab, and low dose rituximab: A phase II clinical trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2014

At a glance

  • Drugs Alemtuzumab (Primary) ; Pentostatin (Primary) ; Rituximab (Primary) ; Sargramostim
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Dec 2012 New source identified and integrated (Mayo Clinic).
    • 24 Oct 2012 Planned end date changed from 1 Sep 2010 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top